Cited by 995Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Comparative effectiveness of different treatment pathways for opioid use disorder.

Open access

Wakeman, Sarah E., Larochelle, Marc R., Ameli, Omid, Chaisson, Christine E., McPheeters, Jeffrey Thomas, Crown, William H., Azocar, Francisca, Sanghavi, Darshak M.·2020·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.20622PMC PMC11143463

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.20622

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citation
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

Flagged first, then by citations

Show all 39 references

3 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 995

Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing
Stopka, T. J., Babineau, D. C., Gibson, E. B., Knott, C. E., Cheng, D. M., Villani, J., Wai, J. M., Blevins, D., David, J. L., Goddard‐Eckrich, D., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0132 · Cited by 6
Association of buprenorphine retention and subsequent adverse outcomes following non-fatal overdose: An analysis using statewide linked Maryland databases
Sugarman, O. K., Saloner, B. K., Richards, T. M., Lasser, E. C., Heath, T., Idries, S., Weiner, J. P., & Bandara, S. N. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111281 · Cited by 6
Barriers and Facilitators to Using a Clinical Decision Support Tool for Opioid Use Disorder in Primary Care
Hooker, S. A., Solberg, L. I., Miley, K. M., Borgert-Spaniol, C. M., & Rossom, R. C. (2024) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2023.230308r1 · Cited by 6
Barriers to retention in inpatient and residential drug treatment among persons who use opioids and/or injection drugs living in the rural U.S.
Fredericksen, R. J., Mixson, L. S., Estadt, A. T., Leichtling, G. J., Bresett, J., Zule, W. A., Walters, S. M., Friedmann, P. D., Romo, E., Whitney, B. M., et al. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209453 · Cited by 6
Buprenorphine Administration and Prescribing at Emergency Departments: A National Analysis From 2014–2021
Ramdin, C., McGowan, T., Perrone, J., Mazer-Amirshahi, M. E., & Nelson, L. S. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001402 · Cited by 6
Implementing and documenting cultural adaption of evidence-based practice strategies to reduce opioid overdose deaths: examples and lessons from the HEALing communities study
Gibson, E. B., Glasgow, L., Nouvong, M., McGladrey, M., Freedman, D. A., Chassler, D., Vickers‐Smith, R., D’Onfro, M., Goddard‐Eckrich, D., Hunt, T., et al. (2025) · Discover Public Health · doi:10.1186/s12982-025-00696-2 · Cited by 6
Treating Opioid Use Disorder in Correctional Settings
Simon, R., Rich, J. D., & Wakeman, S. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1_6 · Cited by 6
Self-citation
Psychosocial Needs of Parents Engaged in Treatment for Opioid Use Disorder
Sattler, A. F., Hooker, S. A., Levy, R. J., & Sherman, M. D. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1981386 · Cited by 6
Project BETTER: A Family-Centered, Technology-Delivered Intervention for Pregnant People with Opioid Use Disorder
Parlier‐Ahmad, A. B., Eglovitch, M., Martin, S., Svikis, D. S., & Martin, C. E. (2023) · Children · doi:10.3390/children10020359 · Cited by 6
Opioid‐related policy changes: Experiences and perspectives from people who use opioids to manage non‐cancer chronic pain
Haines, S., Savic, M., Nielsen, S., & Carter, A. (2023) · Drug and Alcohol Review · doi:10.1111/dar.13683 · Cited by 7
Internalized stigma measurement in substance use treatment settings: a narrative review
Joseph, V. W., Pearson, M. R., & Witkiewitz, K. A. (2023) · Addiction Research & Theory · doi:10.1080/16066359.2023.2227090 · Cited by 31
Emergency Department Pain Management in the Older Adult
Elder, N. M., Heavey, S. F., & Tyler, K. R. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2023.05.012 · Cited by 6
A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States
Chiosi, J. J., Mueller, P. P., Chhatwal, J., & Ciaranello, A. L. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09773-1 · Cited by 6
Willingness to utilize a mobile treatment unit in five counties at the epicenter of the US rural opioid epidemic
Peddireddy, S. R., Livingston, M. D., Young, A. M., Freeman, P. R., Ibragimov, U., Komro, K. A., Lofwall, M. R., Oser, C. B., Staton, M., & Cooper, H. L. F. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209262 · Cited by 6
Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings
Wyse, J. J. B., Eckhardt, A. C., Newell, S., Gordon, A. J., Morasco, B. J., Carlson, K. F., Korthuis, P. T., Ono, S. S., & Lovejoy, T. I. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08898-1 · Cited by 6
Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration
Zhang, Y., Collins, D., Butelman, E. R., Blendy, J. A., & Kreek, M. J. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108351 · Cited by 6
Longitudinal assessment of mental health and well-being in patients being treated with medications for opioid use disorder in primary care
Hooker, S. A., Lonergan, M. E., Levy, R. J., Nissly, T. J., & Sherman, M. D. (2021) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2021.100348 · Cited by 6
Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics
Nguyen, T. D., Andraka‐Christou, B., Bradford, W. D., & Simon, K. I. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000911 · Cited by 6
What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
Gazzola, M. G., Maclean, E., Beitel, M., Carmichael, I. D., Cammack, K. M., Eggert, K. F., Roehrich, T., Madden, L. M., Jegede, O. O., Zheng, X., et al. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07813-w · Cited by 6
Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs
Sue, K. L., Chawarski, M. C., Curry, L. A., McNeil, R., Coupet, E., Schwartz, R. P., Wilder, C. M., Tsui, J. I., Hawk, K. F., D’Onofrio, G., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.12718 · Cited by 8
Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures
Dai, Z., Abate, M. A., Winstanley, E. L., Kraner, J. C., Lundstrom, E. W., Mock, A. R., & Smith, G. S. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209252 · Cited by 5
Beliefs of US chiefs of police about substance use disorder, fentanyl exposure, overdose response, and use of discretion: results from a national survey
Bailey, A., Andraka‐Christou, B., Rouhani, S., Clark, M. H., Atkins, D. N., & del Pozo, B. (2025) · Health & Justice · doi:10.1186/s40352-025-00318-8 · Cited by 5
Impact of Co-Occurring Psychiatric Comorbidities and Substance Use Disorders on Outcomes in Adolescents and Young Adults with Opioid Use Disorder: A Retrospective Cohort Study
Liu, L., McKnight, E. R., Bonny, A. E., Tao, H., Zhao, P., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050609 · Cited by 5
Adolescent Treatment Landscape of Depression, Suicidality, and Substance Use Disorder in the US
Lee, D. M., Dusetzina, S. B., Patrick, S. W., Graves, J. A., & Fry, C. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.2647 · Cited by 5
Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022
Bicket, M. C., Qi, X., Buchwalder, K., Chua, K., Lagisetty, P., Gunaseelan, V., Waljee, J. F., Brummett, C. M., Li, Y., & Nguyen, T. D. (2025) · Anesthesiology · doi:10.1097/aln.0000000000005771 · Cited by 5
Low-Threshold Buprenorphine in Non-Traditional Settings: A Scoping Review
Patterson, A., Davis, Z., Smith, M., Adebayo, N., Perez, M., Guzman, M., Griffin, T., Watson, D. P., Poorman, E. A., Karnik, N. S., et al. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251371854 · Cited by 5
Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration
Woods, R. H. (2023) · Current Drug Safety · doi:10.2174/1574886318666230731151447 · Cited by 5
Offering nurse care management for opioid use disorder in primary care: Impact on emergency and hospital utilization in a cluster-randomized implementation trial
Bobb, J. F., Idu, A., Qiu, H., Yu, O., Boudreau, D. M., Wartko, P. D., Matthews, A. G., McCormack, J., Lee, A. K., Campbell, C. I., et al. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111350 · Cited by 5
Linkage to Care Outcomes Following Treatment in A Low-Threshold Substance Use Disorder Bridge Clinic
Casey, S. K., Howard, S., Regan, S., Romero, A. M., Powell, E. A., Kehoe, L., Kane, M. T., & Wakeman, S. E. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241261609 · Cited by 5
Self-citation
Exploring Opioid Prescription Patterns and Overdose Rates in South Carolina (2017–2021): Insights into Rising Deaths in High-Risk Areas
Sahebi-Fakhrabad, A., Sadeghi, A. H., Kemahlıoğlu‐Ziya, E., & Handfield, R. (2024) · Healthcare · doi:10.3390/healthcare12131268 · Cited by 5
Post-operative pain control in patients on buprenorphine or methadone for opioid use disorder
Quaye, A., Tsafnat, T., Richard, J. M., Stoddard, H., & Gagnon, D. J. (2024) · Journal of Opioid Management · doi:10.5055/jom.0823 · Cited by 5
Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type
Hayes, C. J., Raciborski, R. A., Nowak, M., Acharya, M., Nunes, E. V., & Winhusen, T. M. (2024) · Addiction · doi:10.1111/add.16659 · Cited by 5
Medicaid managed care restrictions on medications for the treatment of opioid use disorder
Stewart, M. T., Andrews, C. M., Feltus, S. R., Hodgkin, D., Horgan, C. M., Parks, C. L., & Nong, T. (2024) · Health Services Research · doi:10.1111/1475-6773.14394 · Cited by 5
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort
Reif, S., Stewart, M. T., Daily, S. M., Brolin, M. F., Lee, M. T., Panas, L., Ritter, G. A., Shields, M. C., Mazel, S. B., & Wicks, J. J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209544 · Cited by 5
Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020
Presskreischer, R., Mojtabai, R., Mauro, C., Zhang, Z., Wall, M. M., & Olfson, M. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209568 · Cited by 5
The effects of message framing on US police chiefs’ support for interventions for opioid use disorder: a randomized survey experiment
del Pozo, B., Rouhani, S., Bailey, A., Clark, M. H., Martins, K. F., Ahmed, F. Z., Atkins, D. N., & Andraka‐Christou, B. (2024) · Health & Justice · doi:10.1186/s40352-024-00306-4 · Cited by 5
The first five years of implementing Missouri's medication first approach to opioid use disorder treatment: Plateaus, regressions, and underbellies of progress
Winograd, R., Park, B., Coffey, B., Ghonasgi, R., Blanchard, B., Thater, P., & Brown, K. C. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209622 · Cited by 4
A randomized, sham-controlled clinical trial to evaluate the NET Device™ for reducing withdrawal symptom severity during opioid discontinuation
Greenwald, M. K., Arfken, C. L., & Winston, J. R. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1510428 · Cited by 5
Methadone Patient Access to Collaborative Treatment: Protocol for a Pilot and a Randomized Controlled Trial to Establish Feasibility of Adoption and Impact on Methadone Treatment Delivery and Patient Outcomes
Meyerson, B. E., Davis, A., Crosby, R. A., Linde-Krieger, L. B., Brady, B. R., Carter, G. A., Mahoney, A. N., Frank, D., Rothers, J., Coffee, Z. H., et al. (2025) · JMIR Research Protocols · doi:10.2196/69829 · Cited by 5
Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach
Silwal, A., Bohler, R. M., Hunt, T., Olvera, R. G., Lofwall, M. R., Cook, C., Marks, K. R., Bridden, C. L., Freeman, P. R., Nouvong, M., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104851 · Cited by 5
Adolescent and Young Adult Access to Opioid Use Disorder Care
Ball, A., Winstead, T., Singh, S., Floyd, A. S., & Banta‐Green, C. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-070224 · Cited by 5
Barriers to effective care: Specialty drug treatment in Philadelphia
Hudgins, A., Uzwiak, B. A., Pizzicato, L. N., & Viner, K. M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108639 · Cited by 5
Subtypes of patients with opioid use disorder in methadone maintenance treatment: A pathways model analysis
Lister, J. J., Yoon, M., Nower, L., Ellis, J. D., & Ledgerwood, D. M. (2022) · International Gambling Studies · doi:10.1080/14459795.2022.2044502 · Cited by 5
Accelerating Opioid Use Disorders Research by Integrating Multiple Data Modalities
Bianchi, S. B., Jeffery, A. D., Samuels, D. C., Schirle, L. M., Palmer, A. A., & Sanchez‐Roige, S. (2022) · Complex Psychiatry · doi:10.1159/000525079 · Cited by 5
Associations Between Distinct Co-occurring Substance Use Disorders and Receipt of Medications for Opioid Use Disorder in the Veterans Health Administration
Frost, M. C., Hawkins, E. J., Glass, J. E., Hallgren, K. A., & Williams, E. C. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001095 · Cited by 5
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update
Leyrer‐Jackson, J. M., Acuña, A. M., & Olive, M. F. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2140039 · Cited by 5
Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder
Clingan, S. E., Cousins, S. J., Lin, C., Nguyen, T. E., Hser, Y., & Mooney, L. J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2169342 · Cited by 5
Applied machine learning analysis: Factors correlated with injection drug use and post-prison medication for opioid use disorder treatment engagement
Victor, G. A., Roddy, A. L., Lenz, D., Willis, T. M., & Kubiak, S. P. (2023) · Journal of Offender Rehabilitation · doi:10.1080/10509674.2023.2213693 · Cited by 5
Barriers, perceived benefits and preferences to exercise in adults with an opioid use disorder in the U.S
Nock, N. L., Hernández, E., Robinson, D. N., Hoffer, L., & Wachholtz, A. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102393 · Cited by 5
Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
Bromberg, D. J., de Leon, S. J. G., Litz, T., Azbel, L., Liberman, A. R., Polonsky, M., Дворяк, С., Saichuk, N., Taxman, F. S., & Altice, F. L. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002349 · Cited by 5
Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
Bergman, A. A., Oberman, R. S., Taylor, S. L., Kranke, B. O., & Chang, E. T. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08703-z · Cited by 5
Cancer Pain Management in Patients with Opioid Use Disorder
Nickels, K., Kullgren, J. G., Mitchell, M. T., Carter, M., Kasberg, B., Holbein, M., Gamble, A., Thompson, B., Koolwal, A., & Ho, J. J. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00577-9 · Cited by 5
A retrospective analysis of perioperative medications for opioid‐use disorder and tapering additional postsurgical opioids via a transitional pain service
Liu, O., Leon, D., Gough, E. K., Speed, T. J., Hanna, M. N., & Jaremko, K. M. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16118 · Cited by 5
Injectable Buprenorphine: An Opportunity to Improve Treatment Access for Youth With Opioid Use Disorder
Calihan, J. B., & Bagley, S. M. (2024) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2024.04.010 · Cited by 5
Improving access to buprenorphine for rural veterans in a learning health care system
Wyse, J. J. B., Mackey, K., Kauzlarich, K., Morasco, B. J., Carlson, K. F., Gordon, A. J., Korthuis, P. T., Eckhardt, A. C., Newell, S., Ono, S. S., et al. (2024) · Health Services Research · doi:10.1111/1475-6773.14346 · Cited by 5
Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages
Gilbert, M. K., Daughton, A. R., Chilcoat, H. D., Laffont, C. M., Strafford, S., & DeVeaugh‐Geiss, A. (2025) · Journal of Medical Internet Research · doi:10.2196/71245 · Cited by 5
Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
Kaski, S. W., Marshalek, P. J., Herschler, J., Wen, S., & Zheng, W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050973 · Cited by 5
Technology-assisted opioid education for out-of-treatment adults with opioid use disorder.
Toegel, F., Novak, M. D., Rodewald, A. M., Leoutsakos, J., Silverman, K., & Holtyn, A. F. (2021) · Psychology of Addictive Behaviors · doi:10.1037/adb0000769 · Cited by 5
Expanding Buprenorphine Use in Primary Care: Changing the Culture
Leiser, A., & Robles, M. (2022) · The Permanente Journal · doi:10.7812/tpp/21.203 · Cited by 5
Subcutaneous Extended-release Buprenorphine Depot Misdiagnosed as an Abscess Resulting in Incision and Drainage and Disruption of Opioid Use Disorder Treatment
Gray, J. R., Kehoe, L. G., Peckham, A. M., & Wakeman, S. E. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001067 · Cited by 5
Self-citation
Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs
Ohlendorf, E., Perez-Correa, A., Riback, L. R., Ghiroli, M. M., López‐Castro, T., & Fox, A. D. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001093 · Cited by 5
Prevalence, Distribution, and Characteristics Associated With Possession of Buprenorphine Waivers Among Infectious Diseases Physicians in the United States
Fujita, A. W., Loughry, N., Moore, D., Carter, A. E., Hussen, S. A., Cooper, H. L. F., Colasanti, J. A., & Sheth, A. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac909 · Cited by 5
Medical Complications of Injection Drug Use — Part II
Rich, K. M., & Solomon, D. A. (2023) · NEJM Evidence · doi:10.1056/evidra2300019 · Cited by 5
Effects of inhaled low-concentration xenon gas on naltrexone-precipitated withdrawal symptoms in morphine-dependent mice
Kaufman, M. J., Meloni, E. G., Qrareya, A. N., Paronis, C. A., & Bogin, V. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110967 · Cited by 5
“You Do More Difficult Things Than This”: A National Study of Nurse Practitioner Buprenorphine Prescribing
Speight, C., Perry, J., & Smirnova, O. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104917 · Cited by 5
Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios
Tatara, E. R., Lin, Q., Ozik, J., Kolak, M., Collier, N. T., Halpern, D., Anselin, L., Dahari, H., Boodram, B., & Schneider, J. A. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012307 · Cited by 5
Receptor‐centric solutions for the opioid epidemic: Making the opioid user impervious to overdose death
Stevens, C. W. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24636 · Cited by 5
Systematic review and meta-analysis to estimate the burden of fatal and non-fatal overdose among people who inject drugsPreprint
Shealey, J., Hall, E. W., Pigott, T., & Bradley, H. M. (2022) · medRxiv · doi:10.1101/2022.02.18.22271192 · Cited by 5
Access to and predictors of substance use treatment and support among people experiencing incarceration in the United States: Analysis of a national cross-sectional study
Chen, S. J., Pollack, H. A., Salisbury‐Afshar, E., & Pho, M. T. (2025) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2025.100343 · Cited by 4
Trauma-Related Stress and Resilience in a Multistate Sample of Methadone Treatment Staff
Coffee, Z. H., Linde-Krieger, L. B., Carter, G. A., Brady, B. R., Davis, A., Crosby, R. A., Frank, D., Mahoney, A. N., Najar, S. M., & Meyerson, B. E. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251383239 · Cited by 9
Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review
Shubel, C., Nunnery, M. A., Marley, G. T., Ostrach, B. M. M., & Carpenter, D. M. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100413 · Cited by 4
Pilot Testing an Asynchronous Online Harm Reduction and Pharmacotherapy Stigma Reduction Training for Substance Use Treatment Professionals
Sulzer, S. H., Prevedel, S. M., Barrett, T. S., Mekjian, M., Vincent, M., Frabis, F., Meier, C., Shiverdecker, C. W., Voss, M. W., Cook, P. J., et al. (2024) · Journal of Drug Issues · doi:10.1177/00220426231226223 · Cited by 4
Evidence-based treatment for opioid use disorder is widely unavailable and often discouraged by providers of residential substance use services in North Carolina
Carroll, J. J., Dasgupta, N., Ostrach, B. M. M., El‐Sabawi, T., Dixon, S. K., Morrissey, B., & Saucier, R. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209474 · Cited by 4
Improving Engagement in Residential Treatment for Substance Use Disorders: An Integrated Care Quality Improvement Project for Individuals With Mental Health and Substance Use Disorders
Ramey, F. R., Stevenson, E. L., Derouin, A. L., Sharma, S., & Ruhiu, M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105174 · Cited by 4
Trends in opioid exposures among young children reported to United States poison centers from 2016 to 2023
Rosen, P. E., Ramdin, C., Leonard, J., Ruck, B. E., Nelson, L. S., & Calello, D. P. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2401598 · Cited by 4
Empowering Primary Care Nurse Practitioners: A Multilevel Approach to Combating the Opioid Crisis
Coffee, Z. H., Speight, C., Reyes-Walsh, L. M., Foreman, J., Davis‐Dick, L., Vanderah, T. W., & Gordon, J. S. (2024) · Journal of Advanced Nursing · doi:10.1111/jan.16694 · Cited by 4
State-Mandated Opioid Use Disorder Treatment In Maryland Jails Helped Patients Recover Despite Gaps In Care
Kramer, C. T., Lenz, C., Song, M., Sufrin, C., Kennedy‐Hendricks, A., Fingerhood, M., Bandara, S. N., & Saloner, B. K. (2025) · Health Affairs · doi:10.1377/hlthaff.2024.01423 · Cited by 4
Health-related quality of life measures as predictors for recurrent hospitalization and mortality among patients in heroin-assisted treatment
Melis, F., Kvamme, T. L., Tjagvad, C., Eide, D., Thylstrup, B., Clausen, T., & Hesse, M. (2025) · Quality of Life Research · doi:10.1007/s11136-025-04019-5 · Cited by 4
The role of micro-, meso-, and macro-level stigma on the uptake of medications for opioid use disorder (MOUD) among women in the criminal legal system
Quadri, O., Skogseth, E. M., Brant, K., & Jones, A. A. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03863-4 · Cited by 4
Microbiome‐derived metabolites in substance use disorders: Mechanisms and implications
Koperska, M., & Kiraly, D. D. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15416 · Cited by 5
Medicaid: Increased Patient Access To MOUD In Residential Treatment Associated With Facility Openings And Closures, 2012–22
Beetham, T., Newton, H., Ndumele, C. D., Fiellin, D. A., & Busch, S. H. (2025) · Health Affairs · doi:10.1377/hlthaff.2025.00348 · Cited by 4
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes
Leech, A. A., Garbett, S. P., Yu, H. A., McNeer, E. A., Bharadwaj, R. R., Linas, B. P., Graves, J. A., Young, J. L., Su, L., Martin, P., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3067 · Cited by 4
Impact of Substance Use Navigators on Initiation of Treatment for Substance Use Disorders and 30-Day Unplanned Readmission
Campbell, A., Rosen, A. D., SHOPTAW, S. J., Herring, A. A., Jay, D., Moulin, A. K., LaMers, J., Samuels, E. A., & Gietzen, L. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09902-y · Cited by 4
Polydrug overdose mortality caused by synthetic opioids and stimulants: current sex- and age-specific trajectories in United States national data for 2018–2024
Butelman, E. R., Huang, Y., Shastry, S., Manini, A. F., Goldstein, R. Z., & Nelly Alia-klein, A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02284-z · Cited by 4
Patient Satisfaction with Substance Use Disorder Rehabilitation Services: a Qualitative Study
Dhumal, T., Giannetti, V. J., Kamal, K. M., Freyder, P. J., Kulkarni, A., Desai, G. V., & Covvey, J. R. (2020) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-020-09705-5 · Cited by 4
Experiences Using a Multidisciplinary Model for Treating Injection Drug Use Associated Infections: A Qualitative Study
Nolan, N. S., Gleason, E. G., Marks, L. R., Habrock-Bach, T., Liang, S. Y., & Durkin, M. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.924672 · Cited by 4
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting
Carswell, N., Angermaier, G., Castaneda, C. A., & Delgado, F. (2022) · Hospital Practice · doi:10.1080/21548331.2022.2102776 · Cited by 4
Perceptions and Experiences With Evidence-based Treatments Among People Who Use Opioids
Carlberg-Racich, S., Sherrod, D., Swope, K., Brown, D. A., Afshar, M., & Salisbury‐Afshar, E. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001064 · Cited by 4
Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder
Shadowen, H. M., Violante, S., Gataric, A., Goulding, A. N., & Martin, C. E. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100121 · Cited by 4
Emergency Department-Initiated Buprenorphine Treatment in a Population with a High Rate of Homelessness: An Observational Study
Childers, R. C., Castillo, E. M., Cronin, A. O., Swee, S., & Lasoff, D. R. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.12.004 · Cited by 4
Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder
Serdarevic, M., Cvitanovich, M. J., MacDonald, B. R., d’Etienne, J. P., DeMoss, D. S., & Ojha, R. P. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2023.06.014 · Cited by 4
Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
Risby, J., Schlesinger, E., Geminn, W., & Cernasev, A. (2023) · Pharmacy · doi:10.3390/pharmacy11050131 · Cited by 4
Postpartum medication for opioid use disorder outcomes associated with prenatal treatment and neighborhood-level social determinants
Martin, C. E., Britton, E., Shadowen, H. M., Johnson, J., Sabo, R., & Cunningham, P. J. (2023) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2023.101173 · Cited by 4
Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff
Mitchell, S. G., Jester, J., Gryczynski, J., Whitter, M., Fuller, D., Halsted, C., & Schwartz, R. P. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00417-7 · Cited by 4
Substance Use Disorder Treatment Carve Outs in Medicaid Managed Care
Silverman, A., Westlake, M. A., Hinds, O. M., Harris, S. J., Abraham, A. J., Grogan, C. M., & Andrews, C. M. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209357 · Cited by 4
Cripistemologies of Drug Use Against Transinstitutional Carceral Ableism
Linton, M. Q., & Fritsch, K. (2024) · Journal of Literary & Cultural Disability Studies · doi:10.3828/jlcds.2024.6 · Cited by 4
Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
Hammerslag, L. R., Talbert, J., Slavova, S. S., Lei, F., Freeman, P. R., Marks, K. R., Fanucchi, L. C., WALSH, S. L., & Lofwall, M. R. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209391 · Cited by 4
Public preferences for opioid reform in a post-COVID era: Consensus and divides
Mancini, C., & Boehme, H. M. (2024) · Journal of Criminal Justice · doi:10.1016/j.jcrimjus.2024.102210 · Cited by 4
Implementation of medication for opioid use disorder treatment during a natural disaster: The PROUD-LA study
Springgate, B. F., Matta, I., True, G., Doran, H., Torres, W. V., Stevens, E., Holland, E. A., Mott, K. R., Ardoin, T. W., Nixdorff, N., et al. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209469 · Cited by 4
Drug Overdose Death Following Substance Use Disorder Treatment Termination in New York City: A Retrospective Longitudinal Cohort Study
Jordan, A. E., Jette, G., Graham, J. K., Burke, C., & Cunningham, C. O. (2024) · Journal of Urban Health · doi:10.1007/s11524-024-00893-5 · Cited by 4

Authors: Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
Affiliations: Harvard University (US)
Boston University (US)
Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
Optum (United States) (US)
Department of Research, OptumLabs, Cambridge, Massachusetts
Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
UnitedHealth Group (United States) (US)
Corresponding author: Wakeman, Sarah E.
ORCID: Wakeman, Sarah E.
Larochelle, Marc R.
Ameli, Omid
Chaisson, Christine E.
Crown, William H.
Azocar, Francisca
Sanghavi, Darshak M.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2020-02-05
Volume: 3
Issue: 2
Pages: e1920622
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.20622
PMC: PMC11143463
OpenAlex: W3005454586
Cited by: 995
References: 39
Citations by year: 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
FWCI: 92.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Network Open (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
School of Medicine, Boston University (1UL1TR001430)
Laura and John Arnold Foundation
Office of National Drug Control Policy (G1799ONDCP06B)
Hamilton Health Sciences Foundation
National Institutes of Health (UL1TR001430)
Centers for Disease Control and Prevention (U01CE002780)
U.S. Food and Drug Administration (HHSF223200910006I)
Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative effectiveness of different treatment pathways for opioid use disorder.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks